A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib

BACKGROUND: Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Santangelo, Alessandra, Rossato, Marzia, Lombardi, Giuseppe, Benfatto, Salvatore, Lavezzari, Denise, De Salvo, Gian Luca, Indraccolo, Stefano, Dechecchi, Maria Cristina, Prandini, Paola, Gambari, Roberto, Scapoli, Chiara, Di Gennaro, Gianfranco, Caccese, Mario, Eoli, Marica, Rudà, Roberta, Brandes, Alba Ariela, Ibrahim, Toni, Rizzato, Simona, Lolli, Ivan, Lippi, Giuseppe, Delledonne, Massimo, Zagonel, Vittorina, Cabrini, Giulio
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906066/
https://ncbi.nlm.nih.gov/pubmed/32661549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa156
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares